Trodelvy Just Jumped the Line in Breast Cancer Treatment

The Data That Changed Everything

Gilead ran two massive Phase 3 trials to earn this promotion.

ASCENT-03 tested Trodelvy alone against standard chemotherapy in patients who weren't candidates for immunotherapy. Trodelvy cut the risk of cancer progression or death by 38%, with a median progression-free survival (PFS, the time before cancer worsens) of 9.7 months versus 6.9 months for chemo. That's nearly three extra months before the disease advances, which in aggressive TNBC is significant.

ASCENT-04 (also called KEYNOTE-D19, because Merck co-ran it) tested Trodelvy plus Keytruda against the existing standard of Keytruda plus chemotherapy. The combination delivered a 35% reduction in the risk of progression or death. Median PFS jumped to 11.2 months versus 7.8 months for the old regimen. The response rate was higher too: 60% of patients saw their tumors shrink, compared to 53% on Keytruda plus chemo.

Overall survival data hasn't matured yet for either trial, so the full picture is still coming. But the PFS improvements were strong enough that the NCCN (the guideline body oncologists rely on) made Trodelvy a Category 1 preferred first-line treatment across PD-L1 status before the FDA even officially signed off.

Winners, Losers, and a Surprising Frenemy Situation

The obvious winner here is Gilead. Trodelvy generated about $1.3 billion in 2024 sales, mostly from later-line breast cancer. Moving into first-line TNBC roughly doubles the addressable patient pool and means patients start the drug earlier (and stay on it longer). Analysts estimate the TNBC market alone could be worth $3 to $4 billion for Trodelvy. Citi reiterated a Buy rating with a $125 price target, calling Trodelvy a potential "leading treatment option for TNBC regardless of PD-L1 status."

The obvious loser? Traditional chemotherapy. In PD-L1-negative disease, Trodelvy monotherapy directly replaces chemo as the preferred option. In PD-L1-positive disease, Trodelvy swaps in for chemo as Keytruda's partner. Chemo gets benched either way.

The interesting wrinkle is Merck's Keytruda. You might expect it to take a hit, but the competitive dynamics are more nuanced. In PD-L1-positive TNBC, Keytruda doesn't get displaced; it gets a better dance partner. The new standard regimen is Trodelvy plus Keytruda, meaning Merck stays embedded in the first-line treatment. Keytruda's volume in TNBC could actually hold steady or even tick up as better outcomes keep more patients on therapy longer. The real casualty is the chemotherapy backbone that used to accompany it.

Wall Street's consensus: this approval co-opts Keytruda rather than cannibalizing it.

Gilead's Oncology Reinvention Gets Real

This approval is the centerpiece of a much bigger strategic bet. Gilead acquired Trodelvy's original developer, Immunomedics, back in 2020, when the drug had just a single accelerated approval in third-line TNBC. Since then, the company has methodically expanded the label: full approval in later-line TNBC (2021), HR-positive/HER2-negative breast cancer (2023), and now first-line TNBC.

The path hasn't been spotless. Gilead voluntarily withdrew Trodelvy's bladder cancer indication in late 2024 after confirmatory data fell short. But the breast cancer franchise has more than compensated, and the company has set an ambitious target of $10 billion in oncology revenue by the early 2030s, with Trodelvy as the anchor.

Additional trials in HR-positive breast cancer (earlier lines) and non-small cell lung cancer are still running, which could further expand the drug's reach. For a company best known for its HIV and hepatitis C franchises, that kind of oncology diversification is exactly what investors have been waiting for.

The Bottom Line

Trodelvy's leap from relief pitcher to opening day starter changes the treatment map for the most aggressive form of breast cancer. For the first time, patients with metastatic TNBC have access to a targeted therapy from day one, regardless of their PD-L1 status. The clinical data is strong, the guideline endorsements are already in place, and the commercial runway just got a whole lot longer.

For the roughly 50% of metastatic TNBC patients who never made it to a second line of treatment, getting a better drug sooner isn't just a business story. It's the whole point.

Pfizer Just Made the GLP-1 Shot a Once-a-Month Thing

Pfizer's berobenatide just posted Phase 2b data showing a once-monthly GLP-1 shot can deliver competitive weight loss with remarkably few dropouts. Wall Street thinks it's solid but not spectacular, and the real question is whether convenience can beat raw efficacy in a $50B market.